Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases

Patent metadata

Field	Value
Publication number	US-9545450-B2
Application number	US-201214122858-A
Country	US
Kind code	B2
Filing date	May 25, 2012
Priority date	May 27, 2011
Publication date	Jan 17, 2017
Grant date	Jan 17, 2017

Abstract

Described herein are methods of making targeting peptides conjugated to recombinant lysosomal enzymes by modifying the amino (N)-terminus and one or more lysine residues on recombinant human lysosomal enzymes using a first crosslinking agent to give rise to first crosslinking agent modified recombinant human lysosomal enzymes, modifying the first amino acid within a short linker at the amino (N)-terminus on a variant IGF-2 peptide using a second crosslinking agent to give rise to a second crosslinking agent modified variant IGF-2 peptide, and then conjugating the first crosslinking agent modified recombinant human lysosomal enzyme to the second crosslinking agent modified variant IGF-2 peptide containing a short linker. Also described herein are conjugates synthesized characterized as having higher affinities for the IGF2/CI-MPR receptor and cellular uptake using the methods disclosed herein. Also described herein are treatment methods using the disclosed conjugates.

First claim

What is claimed:

1. A method of making a targeting peptide conjugated to a recombinant lysosomal enzyme, the method comprising:
conjugating a first crosslinking agent modified recombinant human lysosomal enzyme to one or more second crosslinking agent modified variant IGF-2 peptides, wherein the first crosslinking agent modified recombinant lysosomal enzyme comprises a recombinant lysosomal enzyme characterized as having a chemically modified N-terminus and one or more modified lysine residues; and
the one or more second cross linking agent modified variant IGF-2 peptides comprise one or more variant IGF-2 peptides comprising a modified amino acid within a short extension linker at the amino (N)-terminus,
wherein
the lysosomal enzyme is selected from the group consisting of human acid α-glucosidase, human acid αgalactosidase A, human acid β-glucuronidase, human acid α-iduronidase A, human acid iduronidate 2-sulfatase, human β-hexosaminidase A, human β-hexosaminidase B, human acid α-mannosidase A, human β-glucocerebrosidase, human acid lipase, and any combinations thereof, and
the one or more variant IGF-2 peptides comprising SEQ ID NO: 2 with one or more of the following modifications with respect to the amino acid sequence of SEQ ID NO:2:
substitution of arginine for glutamic acid at position 6;
deletion of amino acids 1-4 and 6;
deletion of amino acids 1-4, 6 and 7;
deletion of amino acids 1-4 and 6 and substitution of lysine for threonine at position 7;
deletion of amino acids 1-4 and substitution of glycine for glutamic acid at position 6 and substitution of lysine for threonine at position 7;
substitution of leucine for tyrosine at position 27;
substitution of leucine for valine at position 43;
substitution of arginine for lysine at position 65; and
the variant IGF-2 peptide comprises an affinity tag and/or a linker extension region of at least 5 amino acids preceding IGF-2.

2. The method of claim 1 , wherein the short extension linker comprises 5 to 20 amino acid residues.

3. The method of claim 1 , wherein the recombinant human lysosomal enzyme is human acid a-glucosidase (rhGAA).

4. The method of claim 1 , wherein two lysine residues are modified on the recombinant human lysosomal enzyme.

5. The method of claim 1 , wherein the first crosslinking agent comprises N-succinimidyl 6-hydrazinonicotinate acetone (S-Hynic).

6. The method of claim 1 , wherein the second cross linking agent comprises PEG4-pentafluorobezene-4-formylbenzoate (PEG4-PFB).

7. The method of claim 1 , wherein the N-terminus and one or more lysine residues on the recombinant human lysosomal enzyme are modified in a buffer lacking primary amines at about pH 7.3 at about room temperature for about 30 minutes.

8. The method of claim 1 , further comprising purifying the second cross linking agent modified variant IGF-2 peptide containing a short extension linker before conjugating the first crosslinking agent modified recombinant human lysosomal enzyme to the second crosslinking agent modified variant IGF-2 peptide containing a short linker.

9. The method of claim 1 , wherein the first crosslinking agent comprises sulfo-N-hydroxysuccinimide ester-phosphine (sulfo-NHS-phosphine).

10. The method of claim 1 , wherein the first crosslinking agent comprises N-hydroxysuccinimide ester-tetraoxapentadecane acetylene (NHS-PEG4-acetylene).

11. The method of claim 1 , wherein the first crosslinking agent comprises a heterobifunctional cross linker selected from difluorocyclooctyne (DIFO) and dibenzocyclooctyne (DIBO).

12. The method of claim 1 , wherein the second crosslinking agent comprises N-hydroxysuccinimide ester-PEG4-azide (NHS-PEG4-azide).

13. A method of making a targeting peptide conjugated to a recombinant lysosomal enzyme, the method comprising:
conjugating a first crosslinking agent modified recombinant human lysosomal enzyme to one or more second crosslinking agent modified variant IGF-2 peptides, wherein the first crosslinking agent modified recombinant lysosomal enzyme comprises a recombinant lysosomal enzyme characterized as having a chemically modified N-terminus and one or more modified lysine residues; and
the one or more second cross linking agent modified variant IGF-2 peptides comprise one or more variant IGF-2 peptides comprising a modified amino acid within a short extension linker at the amino (N)-terminus,
wherein
the lysosomal enzyme is selected from the group consisting of human acid α-glucosidase, human acid αgalactosidase A, human acid β-glucuronidase, human acid α-iduronidase A, human acid iduronidate 2-sulfatase, human β-hexosaminidase A, human β-hexosaminidase B, human acid α-mannosidase A, human β-glucocerebrosidase, human acid lipase, and any combinations thereof, and
the one or more variant IGF-2 peptides comprises the amino acid sequence of SEQ ID NO: 2.

14. The method of claim 1 , wherein more than one of the modified IGF-2 peptide binds to a single lysosomal enzyme.

Assignees

• Do Hung
• Amicus Therapeutics Inc

Inventors

• Do Hung

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P3/08

  for glucose homeostasis (pancreatic hormones A61P5/48) · CPC title

• C07K2319/21

  containing a His-tag · CPC title

• C07K2319/00

  Fusion polypeptide · CPC title

• C12N9/16

  acting on ester bonds (3.1) · CPC title